AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. GH
  4. [Form 4] Guardant Health, Inc. Insider Trading Activity

[Form 4] Guardant Health, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Guardant Health director Vijaya Gadde received new equity compensation grants on June 18, 2025, consisting of:

  • Stock options to purchase 6,833 shares of common stock at an exercise price of $50.57 per share, expiring June 18, 2035
  • 4,203 Restricted Stock Units (RSUs) with no exercise price

Both the stock options and RSUs will fully vest on the earlier of: (1) the one-year anniversary of the grant date (June 18, 2025) or (2) the date of the next annual stockholders meeting. This equity compensation package appears to be part of standard director compensation. The Form 4 was filed by John G. Saia as attorney-in-fact for Vijaya Gadde on June 20, 2025.

Vijaya Gadde, direttrice di Guardant Health, ha ricevuto il 18 giugno 2025 una nuova assegnazione di compensi in azioni, composta da:

  • Opzioni su azioni per acquistare 6.833 azioni ordinarie a un prezzo di esercizio di 50,57 $ per azione, con scadenza il 18 giugno 2035
  • 4.203 Unit脿 di Azioni Vincolate (RSU) senza prezzo di esercizio

Sia le opzioni che le RSU matureranno completamente alla prima tra: (1) il primo anniversario della data di assegnazione (18 giugno 2025) o (2) la data della prossima assemblea annuale degli azionisti. Questo pacchetto di compensi in azioni sembra far parte della normale remunerazione per i direttori. Il modulo Form 4 猫 stato presentato da John G. Saia in qualit脿 di procuratore di Vijaya Gadde il 20 giugno 2025.

Vijaya Gadde, directora de Guardant Health, recibi贸 nuevas concesiones de compensaci贸n en acciones el 18 de junio de 2025, que consisten en:

  • Opciones para comprar 6,833 acciones comunes a un precio de ejercicio de $50.57 por acci贸n, con vencimiento el 18 de junio de 2035
  • 4,203 Unidades de Acciones Restringidas (RSU) sin precio de ejercicio

Tanto las opciones como las RSU se consolidar谩n completamente en la fecha que ocurra primero entre: (1) el primer aniversario de la fecha de concesi贸n (18 de junio de 2025) o (2) la fecha de la pr贸xima reuni贸n anual de accionistas. Este paquete de compensaci贸n en acciones parece ser parte de la compensaci贸n est谩ndar para directores. El Formulario 4 fue presentado por John G. Saia como apoderado de Vijaya Gadde el 20 de junio de 2025.

Guardant Health鞚� 鞚挫偓 Vijaya Gadde電� 2025雲� 6鞗� 18鞚检棎 雼れ潓瓿� 臧欖潃 靸堧鞖� 欤检嫕 氤挫儊 攵�鞐ゼ 氚涭晿鞀惦媹雼�:

  • 頄夓偓臧赌瓴� $50.57鞐� 氤错喌欤� 6,833欤�毳� 甑Г頃� 靾� 鞛堧姅 鞀ろ啞 鞓奠厴, 毵岆鞚检潃 2035雲� 6鞗� 18鞚�
  • 頄夓偓臧赌瓴╈澊 鞐嗠姅 4,203臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)

鞀ろ啞 鞓奠厴瓿� RSU 氇憪 雼れ潓 霊� 臧�歆� 欷� 牍犽ジ 鞁滌爯鞐� 鞝勳暋 氩犾姢韺呺惄雼堧嫟: (1) 攵�鞐澕鞚� 2025雲� 6鞗� 18鞚茧攵�韯� 1欤茧厔 霕愲姅 (2) 雼れ潓 鞐半 欤检＜齑濏殞鞚�. 鞚� 欤检嫕 氤挫儊 韺偆歆�電� 響滌 鞚挫偓 氤挫儊鞚� 鞚茧秬搿� 氤挫瀰雼堧嫟. Form 4電� 2025雲� 6鞗� 20鞚检棎 Vijaya Gadde鞚� 氩曥爜 雽�毽澑鞚� John G. Saia鞐� 鞚橅暣 鞝滌稖霅橃棃鞀惦媹雼�.

Vijaya Gadde, administratrice de Guardant Health, a re莽u de nouvelles attributions de r茅mun茅ration en actions le 18 juin 2025, comprenant :

  • Des options d'achat portant sur 6 833 actions ordinaires 脿 un prix d'exercice de 50,57 $ par action, expirant le 18 juin 2035
  • 4 203 unit茅s d'actions restreintes (RSU) sans prix d'exercice

Tant les options que les RSU seront enti猫rement acquises 脿 la date la plus proche entre : (1) le premier anniversaire de la date d'attribution (18 juin 2025) ou (2) la date de la prochaine assembl茅e annuelle des actionnaires. Ce plan de r茅mun茅ration en actions semble faire partie de la r茅mun茅ration standard des administrateurs. Le formulaire 4 a 茅t茅 d茅pos茅 par John G. Saia en tant que mandataire de Vijaya Gadde le 20 juin 2025.

Vijaya Gadde, Direktorin von Guardant Health, erhielt am 18. Juni 2025 neue Aktienverg眉tungen, bestehend aus:

  • Optionsscheine zum Kauf von 6.833 Stammaktien zu einem Aus眉bungspreis von 50,57 $ pro Aktie, mit Ablaufdatum 18. Juni 2035
  • 4.203 Restricted Stock Units (RSUs) ohne Aus眉bungspreis

Sowohl die Optionen als auch die RSUs werden vollst盲ndig unverfallbar am fr眉heren Zeitpunkt von: (1) dem einj盲hrigen Jahrestag des Gew盲hrungsdatums (18. Juni 2025) oder (2) dem Datum der n盲chsten j盲hrlichen Hauptversammlung. Dieses Aktienverg眉tungspaket scheint Teil der standardm盲脽igen Direktorenverg眉tung zu sein. Das Formular 4 wurde am 20. Juni 2025 von John G. Saia als Bevollm盲chtigter f眉r Vijaya Gadde eingereicht.

Positive
  • None.
Negative
  • None.

Vijaya Gadde, direttrice di Guardant Health, ha ricevuto il 18 giugno 2025 una nuova assegnazione di compensi in azioni, composta da:

  • Opzioni su azioni per acquistare 6.833 azioni ordinarie a un prezzo di esercizio di 50,57 $ per azione, con scadenza il 18 giugno 2035
  • 4.203 Unit脿 di Azioni Vincolate (RSU) senza prezzo di esercizio

Sia le opzioni che le RSU matureranno completamente alla prima tra: (1) il primo anniversario della data di assegnazione (18 giugno 2025) o (2) la data della prossima assemblea annuale degli azionisti. Questo pacchetto di compensi in azioni sembra far parte della normale remunerazione per i direttori. Il modulo Form 4 猫 stato presentato da John G. Saia in qualit脿 di procuratore di Vijaya Gadde il 20 giugno 2025.

Vijaya Gadde, directora de Guardant Health, recibi贸 nuevas concesiones de compensaci贸n en acciones el 18 de junio de 2025, que consisten en:

  • Opciones para comprar 6,833 acciones comunes a un precio de ejercicio de $50.57 por acci贸n, con vencimiento el 18 de junio de 2035
  • 4,203 Unidades de Acciones Restringidas (RSU) sin precio de ejercicio

Tanto las opciones como las RSU se consolidar谩n completamente en la fecha que ocurra primero entre: (1) el primer aniversario de la fecha de concesi贸n (18 de junio de 2025) o (2) la fecha de la pr贸xima reuni贸n anual de accionistas. Este paquete de compensaci贸n en acciones parece ser parte de la compensaci贸n est谩ndar para directores. El Formulario 4 fue presentado por John G. Saia como apoderado de Vijaya Gadde el 20 de junio de 2025.

Guardant Health鞚� 鞚挫偓 Vijaya Gadde電� 2025雲� 6鞗� 18鞚检棎 雼れ潓瓿� 臧欖潃 靸堧鞖� 欤检嫕 氤挫儊 攵�鞐ゼ 氚涭晿鞀惦媹雼�:

  • 頄夓偓臧赌瓴� $50.57鞐� 氤错喌欤� 6,833欤�毳� 甑Г頃� 靾� 鞛堧姅 鞀ろ啞 鞓奠厴, 毵岆鞚检潃 2035雲� 6鞗� 18鞚�
  • 頄夓偓臧赌瓴╈澊 鞐嗠姅 4,203臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)

鞀ろ啞 鞓奠厴瓿� RSU 氇憪 雼れ潓 霊� 臧�歆� 欷� 牍犽ジ 鞁滌爯鞐� 鞝勳暋 氩犾姢韺呺惄雼堧嫟: (1) 攵�鞐澕鞚� 2025雲� 6鞗� 18鞚茧攵�韯� 1欤茧厔 霕愲姅 (2) 雼れ潓 鞐半 欤检＜齑濏殞鞚�. 鞚� 欤检嫕 氤挫儊 韺偆歆�電� 響滌 鞚挫偓 氤挫儊鞚� 鞚茧秬搿� 氤挫瀰雼堧嫟. Form 4電� 2025雲� 6鞗� 20鞚检棎 Vijaya Gadde鞚� 氩曥爜 雽�毽澑鞚� John G. Saia鞐� 鞚橅暣 鞝滌稖霅橃棃鞀惦媹雼�.

Vijaya Gadde, administratrice de Guardant Health, a re莽u de nouvelles attributions de r茅mun茅ration en actions le 18 juin 2025, comprenant :

  • Des options d'achat portant sur 6 833 actions ordinaires 脿 un prix d'exercice de 50,57 $ par action, expirant le 18 juin 2035
  • 4 203 unit茅s d'actions restreintes (RSU) sans prix d'exercice

Tant les options que les RSU seront enti猫rement acquises 脿 la date la plus proche entre : (1) le premier anniversaire de la date d'attribution (18 juin 2025) ou (2) la date de la prochaine assembl茅e annuelle des actionnaires. Ce plan de r茅mun茅ration en actions semble faire partie de la r茅mun茅ration standard des administrateurs. Le formulaire 4 a 茅t茅 d茅pos茅 par John G. Saia en tant que mandataire de Vijaya Gadde le 20 juin 2025.

Vijaya Gadde, Direktorin von Guardant Health, erhielt am 18. Juni 2025 neue Aktienverg眉tungen, bestehend aus:

  • Optionsscheine zum Kauf von 6.833 Stammaktien zu einem Aus眉bungspreis von 50,57 $ pro Aktie, mit Ablaufdatum 18. Juni 2035
  • 4.203 Restricted Stock Units (RSUs) ohne Aus眉bungspreis

Sowohl die Optionen als auch die RSUs werden vollst盲ndig unverfallbar am fr眉heren Zeitpunkt von: (1) dem einj盲hrigen Jahrestag des Gew盲hrungsdatums (18. Juni 2025) oder (2) dem Datum der n盲chsten j盲hrlichen Hauptversammlung. Dieses Aktienverg眉tungspaket scheint Teil der standardm盲脽igen Direktorenverg眉tung zu sein. Das Formular 4 wurde am 20. Juni 2025 von John G. Saia als Bevollm盲chtigter f眉r Vijaya Gadde eingereicht.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gadde Vijaya
(Last) (First) (Middle)
3100 HANOVER STREET
(Street)
PALO ALTO CA 94304
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $50.57 06/18/2025 A 6,833 (1) 06/18/2035 Common Stock 6,833 $0 6,833 D
Restricted Stock Units $0 06/18/2025 A 4,203 (2) (3) Common Stock 4,203 $0 4,203 D
Explanation of Responses:
1. The stock option vests in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier.
2. The restricted stock units vest in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier.
3. Not applicable for Restricted Stock Units.
Remarks:
/s/ John G. Saia, as attorney-in-fact for Vijaya Gadde 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What stock options did Guardant Health (GH) director Vijaya Gadde receive on June 18, 2025?

Director Vijaya Gadde received 6,833 stock options with an exercise price of $50.57 per share. These options will vest in full on June 18, 2026 (one-year anniversary) or the date of the next annual stockholders meeting, whichever occurs earlier. The options expire on June 18, 2035.

How many Restricted Stock Units (RSUs) were granted to GH director Vijaya Gadde in June 2025?

Vijaya Gadde was granted 4,203 Restricted Stock Units (RSUs) on June 18, 2025. These RSUs will vest in full on the one-year anniversary of the grant date (June 18, 2026) or the date of the next annual stockholders meeting, whichever occurs earlier.

What is the vesting schedule for GH director Vijaya Gadde's June 2025 equity grants?

Both the stock options and RSUs granted to Vijaya Gadde follow the same vesting schedule: they vest 100% on the one-year anniversary of the grant date (June 18, 2026) or the date of the next annual stockholders meeting, whichever occurs earlier.

What is the total value of equity compensation granted to Guardant Health director Vijaya Gadde in June 2025?

The Form 4 shows that Vijaya Gadde received two equity grants: 6,833 stock options with a strike price of $50.57 and 4,203 Restricted Stock Units with a $0 exercise price. Both were granted on June 18, 2025, as part of director compensation. The actual value will depend on GH's stock price performance.
Stock GH logo
Guardant Health

NASDAQ:GH

GH Rankings

#1093 Ranked by Market Cap
N/A Ranked by Dividends

GH Latest News

Aug 15, 2025
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 4, 2025
American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity
Jul 31, 2025
Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference
Jul 30, 2025
Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Jul 30, 2025
Guardant Health and James Van Der Beek Team Up to Raise Awareness About New Advances in Colorectal Cancer Screening for Adults 45+

GH Latest SEC Filings

Aug 6, 2025
[Form 4] Guardant Health, Inc. Insider Trading Activity
Aug 4, 2025
[Form 4] Guardant Health, Inc. Insider Trading Activity
Jul 30, 2025
[10-Q] Guardant Health, Inc. Quarterly Earnings Report
Jul 30, 2025
[8-K] Guardant Health, Inc. Reports Material Event
Jul 18, 2025
[Form 4] Guardant Health, Inc. Insider Trading Activity

GH Stock Data

7.30B
118.23M
4.5%
99.25%
7.7%
Diagnostics & Research
Services-medical Laboratories
United States
PALO ALTO